PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23950643-4 2013 Further, the targeted ligands used in the docetaxel nanoformulations, such as monoclonal antibodies, peptides, folic acid, transferrin, aptamers and hyaluronic acid, are described. Docetaxel 42-51 transferrin Homo sapiens 123-134 34413632-0 2021 Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment. Docetaxel 91-100 transferrin Homo sapiens 0-11 21125861-0 2010 A transferrin receptor-targeted liposomal formulation for docetaxel. Docetaxel 58-67 transferrin Homo sapiens 2-13 34413632-2 2021 A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was designed loading both cisplatin (CIS) and docetaxel (DTX) for the lung cancer treatment. Docetaxel 116-125 transferrin Homo sapiens 2-13 34413632-2 2021 A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was designed loading both cisplatin (CIS) and docetaxel (DTX) for the lung cancer treatment. Docetaxel 127-130 transferrin Homo sapiens 2-13 33545820-1 2021 This work was aimed to formulate transferrin (Tf) receptor targeted gold based theranostic liposomes which contain both docetaxel (DCX) and glutathione reduced gold nanoparticles (AuGSH) for brain-targeted drug delivery and imaging. Docetaxel 120-129 transferrin Homo sapiens 33-44 33545820-1 2021 This work was aimed to formulate transferrin (Tf) receptor targeted gold based theranostic liposomes which contain both docetaxel (DCX) and glutathione reduced gold nanoparticles (AuGSH) for brain-targeted drug delivery and imaging. Docetaxel 131-134 transferrin Homo sapiens 33-44 28869892-0 2017 Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Docetaxel 121-130 transferrin Homo sapiens 63-74 32867624-1 2020 Aim: This work focused on the development of transferrin-conjugated theranostic liposomes consisting of docetaxel (DXL) and upconversion nanoparticles for the diagnosis and treatment of gliomas. Docetaxel 104-113 transferrin Homo sapiens 45-56 32867624-1 2020 Aim: This work focused on the development of transferrin-conjugated theranostic liposomes consisting of docetaxel (DXL) and upconversion nanoparticles for the diagnosis and treatment of gliomas. Docetaxel 115-118 transferrin Homo sapiens 45-56 27158834-0 2016 Targeted Delivery of Docetaxel by Use of Transferrin/Poly(allylamine hydrochloride)-functionalized Graphene Oxide Nanocarrier. Docetaxel 21-30 transferrin Homo sapiens 41-52 27287127-1 2016 The aim of this study was to develop multi-walled carbon nanotubes (MWCNT) which were covalently conjugated with transferrin by carbodiimide chemistry and loaded with docetaxel as a model drug for effective treatment of lung cancer in comparison with the commercial docetaxel injection (Docel ). Docetaxel 167-176 transferrin Homo sapiens 113-124 27287127-1 2016 The aim of this study was to develop multi-walled carbon nanotubes (MWCNT) which were covalently conjugated with transferrin by carbodiimide chemistry and loaded with docetaxel as a model drug for effective treatment of lung cancer in comparison with the commercial docetaxel injection (Docel ). Docetaxel 266-275 transferrin Homo sapiens 113-124 28254282-5 2017 In vivo pharmacokinetic study showed 3.23 and 4.10 folds enhancement in relative bioavailability of docetaxel for non-targeted and transferrin receptor targeted nanoparticles, respectively than Docel . Docetaxel 100-109 transferrin Homo sapiens 131-142 28254282-6 2017 The results have demonstrated that transferrin receptor targeted nanoparticles could enhance the cellular internalization and cytotoxicity of docetaxel via transferrin receptor with improved pharmacokinetics for clinical applications. Docetaxel 142-151 transferrin Homo sapiens 35-46 28254282-6 2017 The results have demonstrated that transferrin receptor targeted nanoparticles could enhance the cellular internalization and cytotoxicity of docetaxel via transferrin receptor with improved pharmacokinetics for clinical applications. Docetaxel 142-151 transferrin Homo sapiens 156-167 28031702-0 2017 Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting. Docetaxel 15-24 transferrin Homo sapiens 60-71 28031702-1 2017 The purpose of this study was to develop the surface modification of docetaxel nanocrystals (DTX-NCs) with apo-Transferrin human (Tf) for improving the cellular uptake and cytotoxicity of DTX. Docetaxel 69-78 transferrin Homo sapiens 111-122 26961144-0 2016 Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. Docetaxel 25-34 transferrin Homo sapiens 0-11 26961144-3 2016 The aim of this work was to formulate transferrin conjugated TPGS coated theranostic liposomes, which contain both docetaxel and quantum dots (QDs) for imaging and therapy of brain cancer. Docetaxel 115-124 transferrin Homo sapiens 38-49 26961144-8 2016 The in-vivo results indicated that transferrin receptor-targeted theranostic liposomes could be a promising carrier for brain theranostics due to nano-sized delivery and its permeability which provided an improved and prolonged brain targeting of docetaxel and QDs in comparison to the non-targeted preparations. Docetaxel 247-256 transferrin Homo sapiens 35-46 26657586-0 2016 Transferrin receptor targeted PLA-TPGS micelles improved efficacy and safety in docetaxel delivery. Docetaxel 80-89 transferrin Homo sapiens 0-11 24154938-0 2014 The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer. Docetaxel 31-40 transferrin Homo sapiens 93-104 24154938-1 2014 To reduce the toxic effect on normal cells and improve the treatment effects of docetaxel, a novel transferrin modified docetaxel-loaded long circulating liposome for ovarian tumor was established for the first time. Docetaxel 80-89 transferrin Homo sapiens 99-110 24154938-1 2014 To reduce the toxic effect on normal cells and improve the treatment effects of docetaxel, a novel transferrin modified docetaxel-loaded long circulating liposome for ovarian tumor was established for the first time. Docetaxel 120-129 transferrin Homo sapiens 99-110 24154938-2 2014 The transferrin-modified long-circulating liposomes loaded with docetaxel (TF-LP-DOC) were prepared by the post-insertion method and exhibited excellent characteristics in terms of particle size, encapsulation efficiency and stability. Docetaxel 64-73 transferrin Homo sapiens 4-15